|
JP4574112B2
(ja)
*
|
2000-05-26 |
2010-11-04 |
シェーリング コーポレイション |
アデノシンａ２ａレセプターアンタゴニスト
|
|
CA2459304A1
(en)
*
|
2001-09-13 |
2003-03-20 |
Schering Corporation |
Combination of an adenosine a2a receptor antagonist and an antidepressant or anxiolytic
|
|
JP4545437B2
(ja)
|
2001-10-15 |
2010-09-15 |
シェーリング コーポレイション |
アデノシンａ２ａ受容体アンタゴニストとしてのイミダゾ（４，３−ｅ）−１，２，４−トリアゾロ（１，５−ｃ）ピリミジン
|
|
FR2832405B1
(fr)
*
|
2001-11-19 |
2004-12-10 |
Sanofi Synthelabo |
Tetrahydropyridyl-alkyl-heterocycles azotes, procede pour leur preparation et compositions pharmaceutiques les contenant
|
|
MXPA04005158A
(es)
|
2001-11-30 |
2004-08-11 |
Schering Corp |
Antagonistas receptores de adenosina a2a biciclica de (1.2.4]- triazol.
|
|
PE20030739A1
(es)
|
2001-11-30 |
2003-08-28 |
Schering Corp |
Antagonistas del receptor de adenosina a2a
|
|
KR20050044593A
(ko)
*
|
2001-11-30 |
2005-05-12 |
쉐링 코포레이션 |
아데노신 Ａ2ａ 수용체 길항제
|
|
KR20150080013A
(ko)
|
2002-01-28 |
2015-07-08 |
교와 핫꼬 기린 가부시키가이샤 |
운동성 질환에 걸린 환자의 치료용 조성물
|
|
US7064204B2
(en)
*
|
2002-05-30 |
2006-06-20 |
King Pharmacueticals Reserch And Development, Inc. |
Pharmaceutically active compounds having a tricyclic pyrazolotriazolopyrimidine ring structure and methods of use
|
|
WO2005044245A1
(en)
*
|
2002-12-19 |
2005-05-19 |
Schering Corporation |
USES OF ADENOSINE A2a RECEPTOR ANTAGONISTS
|
|
US20060106040A1
(en)
*
|
2002-12-19 |
2006-05-18 |
Michael Grzelak |
Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
|
|
EP1618109A2
(en)
|
2003-04-09 |
2006-01-25 |
Biogen Idec MA Inc. |
Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosine receptor antagonists
|
|
MXPA05011366A
(es)
*
|
2003-04-23 |
2005-11-28 |
Schering Corp |
Antagonistas del receptor a2a de 2-alquinil- y 2-alquenil-pirazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pirimidina adenosina.
|
|
KR20060037252A
(ko)
*
|
2003-06-10 |
2006-05-03 |
교와 핫꼬 고교 가부시끼가이샤 |
불안 장애의 치료 방법
|
|
WO2004111004A1
(en)
*
|
2003-06-12 |
2004-12-23 |
Novo Nordisk A/S |
Substituted piperazine carbamates for use as inhibitors of hormone sensitive lipase
|
|
JP4800216B2
(ja)
*
|
2003-10-24 |
2011-10-26 |
エグゼリクシス， インコーポレイテッド |
ｐ７０Ｓ６キナーゼモジュレーターおよび使用方法
|
|
WO2005044819A1
(en)
*
|
2003-10-28 |
2005-05-19 |
Schering Corporation |
Process for preparing substituted 5-amino-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines
|
|
ATE377599T1
(de)
|
2003-12-01 |
2007-11-15 |
Schering Corp |
Verfahren zur herstellung von substituierten 5- aminopyrazolo(4,3-e)-1,2,4-triazolo(1,5- c)pyrimidinen
|
|
ATE516011T1
(de)
*
|
2003-12-19 |
2011-07-15 |
Schering Corp |
Pharmazeutische zusammensetzungen eines a2a rezeptorantagonisten
|
|
DE602005020127D1
(de)
|
2004-04-21 |
2010-05-06 |
Schering Corp |
Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors
|
|
EP2258372B8
(en)
|
2005-06-07 |
2012-12-19 |
Kyowa Hakko Kirin Co., Ltd. |
A2A antagonists for use in the treatment of motor disorders
|
|
JP2009508871A
(ja)
*
|
2005-09-19 |
2009-03-05 |
シェーリング コーポレイション |
アデノシンＡ２ａ受容体アンタゴニストとしての２−ヘテロアリール−ピラゾロ−［４，３−ｅ］−１，２，４−トリアゾロ−［１，５−ｃ］−ピリミジン
|
|
AR056080A1
(es)
|
2005-09-23 |
2007-09-19 |
Schering Corp |
7-[2-[4-(6-fluoro-3-metil-1,2-benciosoxazol-5-il)-1-piperazinil]etil]-2-(1-propinil)-7h-pirazol-[4,3-e]-[1,2,4]-triazol-[1,5-c] -pirimidin-5-amine
|
|
ES2273599B1
(es)
|
2005-10-14 |
2008-06-01 |
Universidad De Barcelona |
Compuestos para el tratamiento de la fibrilacion auricular.
|
|
JP5539717B2
(ja)
*
|
2006-07-14 |
2014-07-02 |
塩野義製薬株式会社 |
オキシム化合物およびその使用
|
|
TW200840566A
(en)
*
|
2006-12-22 |
2008-10-16 |
Esteve Labor Dr |
Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments
|
|
US7723343B2
(en)
*
|
2007-03-30 |
2010-05-25 |
King Pharmaceuticals Research And Development, Inc. |
Adenosine A2A receptor antagonists
|
|
US8669260B2
(en)
*
|
2008-02-29 |
2014-03-11 |
Albert Einstein College Of Medicine Of Yeshiva University |
Ketoconazole-derivative antagonist of human pregnane X receptor and uses thereof
|
|
WO2009111449A1
(en)
|
2008-03-04 |
2009-09-11 |
Schering Corporation |
1,2,4-triazolo[4,3-c]pyrimidin-3-one and pyrazolo [4,3-e] -1,2,4-triazolo [4,3-c] pyrimidin-3-one compounds for use as adenosine a2a receptor antagonists
|
|
US20110064671A1
(en)
|
2008-03-10 |
2011-03-17 |
Cornell University |
Modulation of blood brain barrier permeability
|
|
TWI473614B
(zh)
*
|
2008-05-29 |
2015-02-21 |
Kyowa Hakko Kirin Co Ltd |
Anti-analgesic inhibitors
|
|
MX2011000788A
(es)
*
|
2008-07-23 |
2011-03-21 |
Kyowa Hakko Kirin Co Ltd |
Agente terapeutico para migraña.
|
|
US20100093702A1
(en)
*
|
2008-10-13 |
2010-04-15 |
Barbay J Kent |
METHYLENE AMINES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
|
|
EP2379556A1
(en)
|
2008-12-30 |
2011-10-26 |
ArQule, Inc. |
Substituted 1h-pyrazolo[3,4-d]pyrimidine-6-amine compounds
|
|
EP2389175A1
(en)
|
2009-01-20 |
2011-11-30 |
Schering Corporation |
Methods of alleviating or treating signs and/or symptoms associated with moderate to severe parkinson's disease
|
|
WO2010084160A1
(en)
|
2009-01-21 |
2010-07-29 |
Oryzon Genomics S.A. |
Phenylcyclopropylamine derivatives and their medical use
|
|
EP2405917B1
(en)
|
2009-03-13 |
2014-04-23 |
Advinus Therapeutics Private Limited |
Substituted fused pyrimidine compounds
|
|
WO2010114894A1
(en)
|
2009-03-31 |
2010-10-07 |
Arqule, Inc. |
Substituted heterocyclic compounds
|
|
WO2010147941A1
(en)
|
2009-06-15 |
2010-12-23 |
Marvell World Trade Ltd. |
System and methods for gamut bounded saturation adaptive color enhancement
|
|
WO2011017299A2
(en)
|
2009-08-07 |
2011-02-10 |
Schering Corporation |
PROCESS FOR PREPARING A 2-ALKYNYL SUBSTITUTED 5-AMINO-PYRAZOLO-[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PYRIMIDINE
|
|
KR101736218B1
(ko)
|
2009-09-25 |
2017-05-16 |
오리존 지노믹스 에스.에이. |
라이신 특이적 디메틸라아제-1 억제제 및 이의 용도
|
|
EP2486002B1
(en)
|
2009-10-09 |
2019-03-27 |
Oryzon Genomics, S.A. |
Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use
|
|
WO2011101861A1
(en)
|
2010-01-29 |
2011-08-25 |
Msn Laboratories Limited |
Process for preparation of dpp-iv inhibitors
|
|
US9186337B2
(en)
|
2010-02-24 |
2015-11-17 |
Oryzon Genomics S.A. |
Lysine demethylase inhibitors for diseases and disorders associated with Hepadnaviridae
|
|
WO2011106574A2
(en)
|
2010-02-24 |
2011-09-01 |
Oryzon Genomics, S.A. |
Inhibitors for antiviral use
|
|
ES2607081T3
(es)
|
2010-04-19 |
2017-03-29 |
Oryzon Genomics, S.A. |
Inhibidores de desmetilasa específica de lisina-1 y su uso
|
|
US9006449B2
(en)
|
2010-07-29 |
2015-04-14 |
Oryzon Genomics, S.A. |
Cyclopropylamine derivatives useful as LSD1 inhibitors
|
|
LT2598482T
(lt)
|
2010-07-29 |
2018-07-10 |
Oryzon Genomics, S.A. |
Demetilazės lsd1 inhibitoriai arilciklopropilamino pagrindu ir jų medicininis panaudojimas
|
|
US9006177B2
(en)
*
|
2010-09-24 |
2015-04-14 |
Advinus Therapeutics Limited |
Fused tricyclic compounds as adenosine receptor antagonist
|
|
US9061966B2
(en)
|
2010-10-08 |
2015-06-23 |
Oryzon Genomics S.A. |
Cyclopropylamine inhibitors of oxidases
|
|
WO2012072713A2
(en)
|
2010-11-30 |
2012-06-07 |
Oryzon Genomics, S.A. |
Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
|
|
WO2012107498A1
(en)
|
2011-02-08 |
2012-08-16 |
Oryzon Genomics S.A. |
Lysine demethylase inhibitors for myeloproliferative disorders
|
|
WO2012129381A1
(en)
*
|
2011-03-22 |
2012-09-27 |
Concert Pharmaceuticals Inc. |
Deuterated preladenant
|
|
WO2012127472A1
(en)
*
|
2011-03-22 |
2012-09-27 |
Mapi Pharma Ltd. |
Process and intermediates for the preparation of preladenant and related compounds
|
|
WO2013024474A1
(en)
*
|
2011-08-18 |
2013-02-21 |
Mapi Phrarma Ltd. |
Polymorphs of preladenant
|
|
SI2776394T1
(sl)
|
2011-10-20 |
2019-05-31 |
Oryzon Genomics, S.A. |
Spojine (hetero)aril ciklopropilamina kot inhibitorji LSD1
|
|
EP3736265A1
(en)
|
2011-10-20 |
2020-11-11 |
Oryzon Genomics, S.A. |
(hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
|
|
WO2014071512A1
(en)
*
|
2012-11-06 |
2014-05-15 |
Universite Laval |
Combination therapy and methods for the treatment of respiratory diseases
|
|
WO2014101120A1
(en)
*
|
2012-12-28 |
2014-07-03 |
Merck Sharp & Dohme Corp. |
Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
|
|
WO2016081290A1
(en)
|
2014-11-18 |
2016-05-26 |
Merck Sharp & Dohme Corp. |
Aminopyrazine compounds with a2a antagonist properties
|
|
WO2016126570A1
(en)
|
2015-02-06 |
2016-08-11 |
Merck Sharp & Dohme Corp. |
Aminoquinazoline compounds as a2a antagonist
|
|
EP3307067B1
(en)
|
2015-06-11 |
2022-11-02 |
Merck Sharp & Dohme LLC |
Aminopyrazine compounds with a2a antagonist properties
|
|
WO2017008205A1
(en)
|
2015-07-10 |
2017-01-19 |
Merck Sharp & Dohme Corp. |
Substituted aminoquinazoline compounds as a2a antagonist
|
|
US9687475B1
(en)
|
2016-03-24 |
2017-06-27 |
Ezra Pharma Llc |
Extended release pharmaceutical formulations with controlled impurity levels
|
|
US9675585B1
(en)
|
2016-03-24 |
2017-06-13 |
Ezra Pharma |
Extended release pharmaceutical formulations
|
|
CN110678472B
(zh)
*
|
2017-03-30 |
2023-01-24 |
伊忒欧斯比利时股份公司 |
作为a2a抑制剂的2-氧代噻唑衍生物和用于治疗癌症的化合物
|
|
WO2018178338A1
(en)
*
|
2017-03-30 |
2018-10-04 |
Iteos Therapeutics |
2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers
|
|
US11498923B2
(en)
|
2017-12-13 |
2022-11-15 |
Merck Sharp & Dohme Llc |
Substituted imidazo[1,2-c]quinazolines as A2A antagonists
|
|
ES2928238T3
(es)
|
2018-01-04 |
2022-11-16 |
Impetis Biosciences Ltd |
Compuestos tricíclicos, composiciones y aplicaciones medicinales de los mismos
|
|
WO2019168847A1
(en)
|
2018-02-27 |
2019-09-06 |
Incyte Corporation |
Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
|
|
CN108276345A
(zh)
*
|
2018-03-22 |
2018-07-13 |
重庆奥舍生物化工有限公司 |
一种药物中间体嘧啶-5-甲醛的制备方法
|
|
CA3095839A1
(en)
*
|
2018-04-08 |
2019-10-17 |
Beigene, Ltd. |
Pyrazolotriazolopyrimidine derivatives as a2a receptor antagonist
|
|
US11168089B2
(en)
|
2018-05-18 |
2021-11-09 |
Incyte Corporation |
Fused pyrimidine derivatives as A2A / A2B inhibitors
|
|
CN108864114B
(zh)
|
2018-06-04 |
2020-11-06 |
应世生物科技(南京)有限公司 |
选择性a2a受体拮抗剂
|
|
JOP20200342A1
(ar)
|
2018-07-05 |
2020-12-30 |
Incyte Corp |
مشتقات بيرازين مدمجة كمثبطات a2a/a2b
|
|
CN110742893B
(zh)
*
|
2018-07-23 |
2024-04-05 |
百济神州(北京)生物科技有限公司 |
A2a受体拮抗剂治疗癌症的方法
|
|
JOP20210117A1
(ar)
|
2018-11-30 |
2023-01-30 |
Merck Sharp & Dohme |
مشتقات أمينو ترايازولو كوينازولين بها استبدال في الموضع-9 كمضادات مستقبل أدينوزين، تركيبات صيدلانية واستخدامها
|
|
CR20210336A
(es)
|
2018-12-20 |
2021-12-06 |
Incyte Corp |
Compuestos de imidazopiridazina e imidazopiridina como inhibidores de quinasa-2 de tipo receptor de activina
|
|
TWI829857B
(zh)
|
2019-01-29 |
2024-01-21 |
美商英塞特公司 |
作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
|
|
WO2020227156A1
(en)
*
|
2019-05-03 |
2020-11-12 |
Nektar Therapeutics |
Adenosine 2 receptor antagonists
|
|
DE102019116986A1
(de)
|
2019-06-24 |
2020-12-24 |
Helmholtz-Zentrum Dresden-Rossendorf E. V. |
Deuterierte 7-(3-(4-(2-([18F]Fluor)ethoxy)phenyl)propyl)-2-(furan-2-yl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amin-Derivate
|
|
EP3999513A4
(en)
*
|
2019-07-17 |
2022-12-21 |
Teon Therapeutics, Inc. |
ADENOSIN A2A RECEPTOR ANTAGONISTS AND USES THEREOF
|
|
CN112625050B
(zh)
|
2019-07-30 |
2021-10-01 |
杭州阿诺生物医药科技有限公司 |
一种a2a和/或a2b受体抑制剂的制备方法
|
|
CN112608316B
(zh)
|
2019-07-30 |
2022-10-21 |
厦门宝太生物科技股份有限公司 |
一种吡唑并三嗪类腺苷受体拮抗剂
|
|
CN111072675A
(zh)
*
|
2019-12-12 |
2020-04-28 |
广东东阳光药业有限公司 |
含氮稠合三环衍生物及其用途
|
|
CN113773327B
(zh)
*
|
2021-09-13 |
2022-07-15 |
八叶草健康产业研究院(厦门)有限公司 |
一种吡唑并嘧啶并三唑环类化合物的制备方法
|
|
CN118812544A
(zh)
*
|
2024-06-19 |
2024-10-22 |
厦门大学 |
一种腺苷a2ar靶向小分子化合物、核素标记探针及其制备方法、应用和药物组合物
|
|
CN118812539B
(zh)
*
|
2024-06-19 |
2025-11-28 |
苏州大学 |
一种5-氨基三唑并嘧啶衍生物及其制备方法
|